Discover
COGT
Cogent Biosciences, Inc.
38.48
1 x 38.27
2 x 49.47
bid
ask
-
0.22
0.57%
2 @ 04:00 PM
39.00 +0.52 (1.35%)
| Ytd | 8.33% | |
| 1y | 432.96% |
38.12
day range
39.40
7.17
52 week range
43.73
| Open | 38.58 | Prev Close | 38.70 | Low | 38.12 | High | 39.40 | Mkt Cap | 6.58B |
| Vol | 2.30M | Avg Vol | 2.34M | EPS | -2.17 | P/E | N/A | Forward P/E | -40.26 |
| Beta | 0.35 | Short Ratio | 5.69 | Inst. Own | 112.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 34.72 | 200-d Avg | 32.08 | 1yr Est | 54.25 |
| Income Statement | |||
| Operating Expenses | 103.61M | ||
| Research and Development Expense | 75.36M | ||
| Selling, General and Administrative Expense | 28.24M | ||
| Operating Income | -103.61M | ||
| Interest Expense | 1.21M | ||
| Net Income | -97.35M | ||
| Net Income Common Stock | -97.35M | ||
| Net Income Common Stock (USD) | -97.35M | ||
| Consolidated Income | -97.35M | ||
| Earnings per Basic Share | -0.53 | ||
| Earnings per Basic Share (USD) | -0.53 | ||
| Earnings per Diluted Share | -0.53 | ||
| Earning Before Interest & Taxes (EBIT) | -96.14M | ||
| Earning Before Interest & Taxes (USD) | -96.14M | ||
| Weighted Average Shares | 162.19M | ||
| Weighted Average Shares Diluted | 162.19M | ||
| Balance Sheet | |||
| Cash and Equivalents | 241.62M | ||
| Cash and Equivalents (USD) | 241.62M | ||
| Investments | 625.17M | ||
| Investments Current | 625.17M | ||
| Current Assets | 877.80M | ||
| Property, Plant & Equipment Net | 22.85M | ||
| Total Assets | 903.01M | ||
| Debt Current | 1.38M | ||
| Total Debt | 238.65M | ||
| Current Liabilities | 57.98M | ||
| Debt Non-Current | 237.27M | ||
| Total Liabilities | 295.31M | ||
| Accumulated Retained Earnings (Deficit) | -1.29B | ||
| Accumulated Other Comprehensive Income | -415.00K | ||
| Shareholders Equity | 607.69M | ||
| Shareholders Equity (USD) | 607.69M | ||
| Assets Non-Current | 25.20M | ||
| Total Debt (USD) | 238.65M | ||
| Liabilities Non-Current | 237.33M | ||
| Trade and Non-Trade Payables | 13.74M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.16M | ||
| Net Cash Flow from Financing | 52.54M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -70.80M | ||
| Capital Expenditure | -449.00K | ||
| Issuance (Purchase) of Equity Shares | 46.77M | ||
| Net Cash Flow from Investing | -36.46M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -36.01M | ||
| Net Cash Flow from Operations | -86.88M | ||
| Share Based Compensation | 16.91M | ||